BTN3A binding proteins and uses thereof
US12247075B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 26, 2019 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Jul 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of Vγ9/Vδ2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated γδ T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.